Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes
Status:
Completed
Trial end date:
2021-02-28
Target enrollment:
Participant gender:
Summary
A frequent complication in the management of diabetic ketoacidosis (DKA) in children with
type 1 diabetes is rebound hyperglycemia (blood glucose over 180 mg/dL) which increases the
risk of re-developing DKA and can lengthen the hospital stay. The investigators want to study
whether giving the long-acting insulin glargine (Lantus®) early in DKA management (versus
after complete resolution of the DKA) helps prevent rebound hyperglycemia and makes the
transition to insulin injections easier. Participants will also have the option to wear a
continuous glucose monitor (CGM) during the study to help us understand blood glucose control
during and after DKA.